UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G
                                 (Rule 13d-102)

                              INFORMATION STATEMENT
                        PURSUANT TO RULES 13d-1 AND 13d-2
                    Under the Securities Exchange Act of 1934
                              (Amendment No. 3)* **

                     	BIOMARIN PHARMACEUTICAL INC
                                (Name of Issuer)

                                  COMMON STOCK
                         (Title of Class of Securities)

                                   09061G 10 1
                                 (CUSIP Number)

*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for any  subsequent  amendment  containing  information  which  would  alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).

**This Amendment No. 3 is Final and Terminating Amendment.






                                  SCHEDULE 13G

CUSIP NO. 09061G 10 1                                          Page 2 of 4 Pages
BIOMARIN PHARMACEUTICAL INC

1.       NAME OF REPORTING PERSON
         S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

                  NEW YORK LIFE INSURANCE COMPANY

                  13-5582869

2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*       (a) [ ]
                                                              (b) [ ]

3.    SEC USE ONLY

4.    CITIZENSHIP OR PLACE OF ORGANIZATION

                  NEW YORK

NUMBER OF                  5.       SOLE VOTING POWER        200,000
SHARES
BENEFICIALLY               6.       SHARED VOTING POWER        0
OWNED BY
EACH                       7.       SOLE DISPOSITIVE POWER   200,000
REPORTING
PERSON                     8.       SHARED DISPOSITIVE POWER   0
WITH

9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
      REPORTING PERSON                                       200,000

10.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
      EXCLUDES CERTAIN SHARES* [ ]

11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9        .32%

12.   TYPE OF REPORTING PERSON*

                  IC

        *SEE INSTRUCTIONS BEFORE FILLING OUT







                                  SCHEDULE 13G

CUSIP NO. 09061G 10 1                                          Page 3 of 4 Pages
BIOMARIN PHARMACEUTICAL INC



Item 1(a)     Name of Issuer:   BIOMARIN PHARMACEUTICAL INC
		Formerly known as Glyko Biomedical LTD. (cusip #379904105)

Item 1(b)     Address of Issuer's principal executive offices:

                                371 Bel Marin Keys BLVD. Suite 210
                                Novato, CA 94949

Item 2(a)     Name of person filing:    NEW YORK LIFE INSURANCE COMPANY

Item 2(b)     Address of principal business office:

                                51 MADISON AVENUE, ROOM 201
                                NEW YORK, NY  10010

Item 2(c)     Citizenship: NEW YORK

Item 2(d)     Title of class of securities: COMMON STOCK

Item 2(e)     Cusip No.:   09061G 10 1

Item 3        Type of Person: INSURANCE COMPANY AS DEFINED IN SECTION 3(A)(19)
                              OF THE ACT

Item 4(a)     Amount beneficially owned:		200,000

Item 4(b)     Percent of class:         .32%

Item 4(c)     (i) sole power to vote:                    200,000
              (ii)shared power to vote:                        0
              (iii)sole power to dispose:		  200,000
              (iv)shared power to dispose:                     0

Item 5        Ownership of 5 percent or less of a class:

              IF THIS STATEMENT IS BEING FILED TO REPORT THE FACT THAT AS OF THE
              DATE HEREOF THE REPORTING  PERSON HAS CEASED TO BE THE  BENEFICIAL
              OWNER OF MORE THAN FIVE PERCENT OF THE CLASS SECURITIES, CHECK THE
              FOLLOWING (X).

Item 6        Ownership of more than 5 percent on behalf of another person:  NOT
              APPLICABLE

Item 7        Identification and classification of subsidiary: NOT APPLICABLE

Item 8        Identification and classification of members of the group:     NOT
              APPLICABLE





                                  SCHEDULE 13G

CUSIP NO. 09061G 10 1                                          Page 4 of 4 Pages
BIOMARIN PHARMACEUTICAL INC




Item 9        Notice of dissolution of the group:     NOT APPLICABLE

Item 10       Certification:

              By signing  below I certify  that, to the best of my knowledge and
              belief,  the  securities  referred  to above were  acquired in the
              ordinary  course of business and were not acquired for the purpose
              of and do not have the  effect  of  changing  or  influencing  the
              control of the issuer of such  securities and were not acquired in
              connection with or as a participant in any transaction having such
              purpose or effect.

                                    SIGNATURE

              After  reasonable  inquiry  and to the  best of my  knowledge  and
              belief, I certify that the information set forth in this statement
              is true, complete, and correct.

Dated: June 30, 2003                        NEW YORK LIFE INSURANCE COMPANY


                                            By:    /s/ William Y. Cheng
                                                   -----------------------------
                                                   Name:  William Y. Cheng
                                                   Title: Vice President